Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Center, Phase 1, Randomized, Open-Label Bioequivalence Trial in Healthy Volunteers Comparing ACP-011 Administered as a Single Dose via Syringe and Needle vs. Auto-Injector

Trial Profile

A Single Center, Phase 1, Randomized, Open-Label Bioequivalence Trial in Healthy Volunteers Comparing ACP-011 Administered as a Single Dose via Syringe and Needle vs. Auto-Injector

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Sep 2018

At a glance

  • Drugs ACP 001 (Primary)
  • Indications Somatotropin deficiency
  • Focus Pharmacokinetics
  • Sponsors Ascendis Pharma
  • Most Recent Events

    • 05 Sep 2018 Status changed to active, no longer recruiting.
    • 05 Sep 2018 Planned End Date changed from 3 Jan 2018 to 15 Sep 2018.
    • 25 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top